Statutory Profit Doesn't Reflect How Good Veracyte's Earnings Are

💡 Veracyte's statutory profit fails to accurately represent its true earnings potential.

The Federal Reserve delivered a hawkish surprise on Wednesday, signaling that interest rate cuts remain further away than markets had hoped. Fed Chair Jerome Powell told reporters that the central bank needs "greater confidence" that inflation is sustainably declining before it will consider easing policy.

The 10-year Treasury yield surged to 4.8% in the aftermath, its highest level since October 2023. $TLT fell sharply as bond traders repriced the timing of the first cut from March to June.

Veracyte's Statutory Profit Discrepancies

Veracyte's ($VCYT) statutory profit doesn't accurately reflect the company's true earnings potential. The discrepancy between its statutory profit and adjusted earnings is largely due to non-cash expenses, such as share-based compensation and amortization of intangible assets.

Veracyte's Revenue Growth

Veracyte's revenue has been steadily increasing, driven by the growing adoption of its molecular diagnostic tests. The company's Afirma test has become the standard of care for thyroid nodule diagnosis, and its Percept test has shown promising results in lung cancer diagnosis.

Veracyte's Adjusted Earnings

Veracyte's adjusted earnings per share have been consistently higher than its statutory profit. This is because the company's adjusted earnings exclude non-cash expenses, such as share-based compensation and amortization of intangible assets. By excluding these expenses, Veracyte's adjusted earnings provide a more accurate representation of its true earnings potential.

What It Means for Investors